Product Image

Boost

NaturesPlus BrainCeutix
4.7
★ ★ ★ ★ ★
(349 ratings)
Huperzine 100 mcg
Acetyl L-Carnitine 75 mg
Choline 10 mg
Ginkgo
Bacopa 50 mg
Product Image
Score68
A broad stimulant-free cognitive stack with useful phosphatidylserine and huperzine, but uneven supporting doses, label ambiguity, and high cost hold it back.
How scoring works
Quantity:90 Capsule(s) • (30 servings)
Goals:
Brain Health
Mental Focus
Productivity Boost
Cognitive Support

Score 68

A broad stimulant-free cognitive stack with useful phosphatidylserine and huperzine, but uneven supporting doses, label ambiguity, and high cost hold it back.
How scoring works
$48.03($1.60 per serving)
iHerb
$ 48.41
Pure Formulas
$ 48.41
Vitacost
$ 48.43
Amazon
$ 48.03
Report prices

Analysis

Phosphatidylserine at 100 mg, N-acetylcysteine at 200 mg, alpha-lipoic acid, and 100 mcg huperzine A provide the clearest cognitive and antioxidant support. PQQ and a small amount of astaxanthin extend the mitochondrial theme.

Choline, acetyl-L-carnitine, bacopa, and ginkgo are included at modest amounts or without useful standardization details. The duplicated alpha-lipoic acid entries should also be checked against the current label to confirm the actual total.

The formula may appeal to adults seeking a stimulant-free cognitive stack with a strong cholinergic component. Huperzine's interaction profile and the high serving cost make it less suitable for casual daily use.

Who is it for
  • Adults seeking stimulant-free cognitive support
  • Users interested in phosphatidylserine and huperzine
  • People comfortable with a complex formula
Best for
  • Mental focus support
  • Cholinergic pathway support
  • Cognitive antioxidant coverage

Pros

  • Provides 100 mg phosphatidylserine
  • Clearly states 100 mcg huperzine A
  • Includes N-acetylcysteine and alpha-lipoic acid
  • Covers several cognitive pathways without caffeine

Cons

  • Bacopa and choline amounts are low
  • Ginkgo lacks standardization detail
  • Alpha-lipoic acid entries appear duplicated
  • High serving cost

Warnings

  • Huperzine may interact with cholinergic or anticholinergic medicines and can cause nausea, vivid dreams, or a slow heartbeat
  • Ginkgo may add to bleeding risk with anticoagulant or antiplatelet medicines
  • Alpha-lipoic acid may lower blood glucose and warrants care with glucose-lowering medicines

Nutrient quality

74 High impact

Useful forms of carnitine, lipoic acid, and huperzine support a coherent cognitive blend. Several core actives are modestly dosed and the lipoic-acid listing is ambiguous.

.

Ingredient transparency

68 High impact

The main active amounts are generally available and no broad proprietary blend obscures the formula. Complete usage directions and non-active ingredients are not supplied, while any noted duplicate or vague entries reduce clarity.

.

Customer satisfaction

67 High impact

Aggregate satisfaction is very strong and supported by a substantial evidence base. No firsthand experience details are supplied, so recurring complaints and purpose alignment remain uncertain.

.

Value for money

64 Moderate impact

Broad cognitive coverage provides some formula value. Modest core doses and ambiguous label entries keep it from being highly competitive.

.
Report analysis

Goals

Brain Health
Brain Health
Impact
High effect
A- Goal FitC Strength of SupportB+ CoverageB Formula Quality
Huperzine · 100 mcgBacopa · 50 mg

Phosphatidylserine, huperzine A, bacopa, ginkgo, acetyl-L-carnitine, and mitochondrial antioxidants directly target memory and cognitive resilience. The formula spans cholinergic signaling, neuronal membranes, circulation, and brain energy.

Huperzine A is meaningfully dosed, but acetyl-L-carnitine and bacopa are low and bacopa lacks a clear active percentage. Huperzine A may cause nausea, insomnia, or a slow heart rate and can interact with cholinergic or anticholinergic medicines.

Study evidence
Acetyl L-Carnitine Supportive 19 studies
Bacopa Supportive 17 studies
Ginkgo Supportive 90 studies
Huperzine Supportive 17 studies
Mental Focus
Mental Focus
Impact
High effect
B+ Goal FitC+ Strength of SupportB CoverageB+ Formula Quality
Choline · 10 mgAcetyl L-Carnitine · 75 mgHuperzine · 100 mcg

Phosphatidylserine, huperzine A, alpha-lipoic acid, NAC, PQQ, ginkgo, bacopa, and acetyl-L-carnitine cover membrane, cholinergic, antioxidant, and mitochondrial pathways. Huperzine A and phosphatidylserine reach practical amounts.

Acetyl-L-carnitine, bacopa, ginkgo, PQQ, and astaxanthin are below stronger cognitive ranges, creating broad but shallow coverage. Huperzine A may cause nausea, slow heart rate, or sleep disturbance, while ginkgo may increase bleeding risk with anticoagulants.

Study evidence
Acetyl L-Carnitine Supportive 7 studies
Bacopa Supportive 13 studies
Ginkgo Supportive 28 studies
Huperzine Not classified

No linked studies yet.

Productivity Boost
Productivity Boost
Impact
High effect
B+ Goal FitC- Strength of SupportB CoverageB+ Formula Quality
Acetyl L-Carnitine · 75 mgAcetyl L-Carnitine · 75 mgHuperzine · 100 mcg

Phosphatidylserine, huperzine A, ginkgo, bacopa, acetyl-L-carnitine, lipoic acid, and PQQ directly target memory, attention, and cellular energy. Several actives have human cognitive evidence, but bacopa, ginkgo, and acetyl-L-carnitine are below common study amounts or lack standardization.

Huperzine A and phosphatidylserine have meaningful amounts, while bacopa at 50 mg and acetyl-L-carnitine at 75 mg are substantially underdosed. Most amounts are disclosed, but ginkgo and bacopa lack active-marker standardization and the whole-food blend is opaque. Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines, while huperzine A may cause nausea, slow heart rate, or sleep disturbance.

Study evidence
Acetyl L-Carnitine Supportive 1 study
Acetyl L-Carnitine Supportive 1 study
Bacopa Supportive 12 studies
Ginkgo Supportive 20 studies
Ginkgo Supportive 12 studies
Huperzine No effect 1 study
Cognitive Support
Cognitive Support
Impact
High effect
B Goal FitC Strength of SupportB CoverageB- Formula Quality
Choline · 10 mgAstaxanthin · 300 mcgHuperzine · 100 mcgAcetyl L-Carnitine · 75 mgBacopa · 50 mg

Phosphatidylserine and a well-targeted huperzine A amount provide meaningful support for memory signaling. Ginkgo, bacopa, and acetyl-L-carnitine broaden the stack, but their amounts are too low for strong standalone effects.

The formula covers cholinergic signaling, cell membranes, circulation, and cognitive energy, though depth is uneven. Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines, while huperzine A may cause cholinergic effects and can interact with cholinergic or anticholinergic drugs.

Study evidence
Acetyl L-Carnitine Supportive 20 studies
Bacopa Supportive 30 studies
Choline Supportive 76 studies
Ginkgo Supportive 87 studies
Huperzine Supportive 22 studies

Ingredients

IngredientAmount per serving
Olive leaf extract (Oleuropein)
 5 mg
Choline (Choline Bitartrate)
 10 mg
N-Acetyl-L-Cysteine
200 mg
Lipoic Acid (Alpha Lipoic, R-Lipoic Acid)
 120 mg
Phosphatidylserine (Phosphatidylserine Complex)
 100 mg
Acetyl-L-Carnitine (Acetyl-L-Carnitine HCl)
 75 mg
Ginkgo biloba extract
60 mg
Bacopa
50 mg
Pyrroloquinoline Quinone
5 mg
Astaxanthin (Haematoccous pluvialis)
 300 mcg
Huperzine A (Huperzia serrata)
 100 mcg
Brain Support Blue Whole Food Blend
50 mg
Gluten Free Adults 18–50 Vegetarian
Report overview
Huperzine (Huperzia serrata) · 100 mcg OverallScore90
A+ Active Ingredient Quality & BioavailabilityA- Dose, Safety & Label TransparencyB Value

Huperzine A is explicitly identified from Huperzia serrata at a well-targeted 100 mcg amount. Capsule delivery supports precise dosing, but no cycling instructions address its long half-life and possible accumulation. The high cost per active amount is partly justified by phosphatidylserine, acetyl-L-carnitine, ginkgo, bacopa, lipoic acid, and PQQ.

View ingredientView products
Acetyl L-Carnitine (Acetyl-L-Carnitine HCl) · 75 mg OverallScore57
A- Active Ingredient Quality & BioavailabilityD- Dose, Safety & Label TransparencyF Value

Acetyl-L-carnitine HCl is clearly identified, but its 75 mg amount is far below a useful daily range. R-lipoic acid and phosphatidylserine add relevant support, while the exact acetyl L-carnitine dose remains transparent. High dose-specific cost makes it a weak choice when acetyl L-carnitine is the main goal.

View ingredientView products
Choline (Choline Bitartrate) · 10 mg OverallScore50
C+ Active Ingredient Quality & BioavailabilityD Dose, Safety & Label TransparencyF Value

Choline bitartrate is a standard systemic source rather than a premium brain-targeted form. The 10 mg elemental amount is too low for strong standalone impact. The 3-unit serving adds inconvenience, and choline-specific value remains weak.

View ingredientView products
Loading alternative details
75 Performance

Memoractiv

Thorne
<p>It combines 300 mg of KSM-66 ashwagandha, 250 mg of acetyl-L-carnitine, 240 mg of ginkgo phytosome, and 100 mg of bacopa. Compared with the original, the formula uses larger amounts of several core cognitive ingredients and has stronger provided fit for brain health, focus, or cognition.</p>
75 Performance

Brain Cell Support

Metabolic Maintenance
<p>It provides 500 mg of acetyl-L-carnitine, 200 mg of citicoline, 100 mg each of DMAE and phosphatidylserine, and 120 mg of ginkgo extract. Compared with the original, the formula uses larger amounts of several core cognitive ingredients and has stronger provided fit for brain health, focus, or cognition.</p>
76 Performance

Nu Clarity

CogniTune Smarter Health
<p>It combines 300 mg of bacopa, 200 mg of alpha-GPC, 150 mg of acetyl-L-carnitine, 100 mg of phosphatidylserine, and 100 mcg of huperzine A. Compared with the original, the formula uses larger amounts of several core cognitive ingredients and has stronger provided fit for brain health, focus, or cognition.</p>
76 Budget

Ultimate Neuro Complex

Natural Factors 3 Brains
<p>It provides 666 mg of acetyl-L-carnitine, 400 mg of NAC, 200 mg of alpha-lipoic acid, 80 mg of ginkgo, and 100 mcg of huperzine A. It costs less per serving than the original while retaining several ingredients tied to its brain-health and focus goals.</p>
76 Budget

Brain Elevate

NOW
<p>It combines 50 mg of choline, 60 mg of ginkgo extract, 15 mg of phosphatidylserine, and 25 mcg of a huperzine complex. It costs less per serving than the original while retaining several ingredients tied to its brain-health and focus goals.</p>
76 Budget

Pure Brainpower

Swanson
<p>It combines 300 mg of Bacognize bacopa, 75 mg of ginkgo extract, and 100 mg of coffee-fruit extract. It costs less per serving than the original while retaining several ingredients tied to its brain-health and focus goals.</p>
78 Value

Ginkgo+

NS Natural Stacks
<p>It combines 200 mg each of ginseng and bacopa with 125 mg of ginkgo extract. It offers a useful balance of ingredient breadth, cognitive-goal fit, and serving cost compared with the original’s much higher ongoing cost.</p>
77 Value

Memory Complex

Natrol
<p>It provides 300 mg of bacopa, 120 mg of ginkgo extract, 10 mg of phosphatidylserine, 5 mcg of huperzine A, and several B vitamins. It offers a useful balance of ingredient breadth, cognitive-goal fit, and serving cost compared with the original’s much higher ongoing cost.</p>
70 Value

Brain Regain

Protocol For Life Balance
<p>It combines 50 mg of choline, 60 mg of ginkgo extract, 15 mg of phosphatidylserine, 25 mcg of a huperzine complex, glutamine, and gotu kola. It offers a useful balance of ingredient breadth, cognitive-goal fit, and serving cost compared with the original’s much higher ongoing cost.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
    Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS; Alzheimer's Disease Cooperative Study · Neurology · 2011
    Randomized trial210 participantsCognitive Support forHuperzine
  2. Huperzine A for vascular dementia.
    Hao Z; Liu M; Liu Z; Lv D · The Cochrane database of systematic reviews · 2009
    Systematic review14 participants1 studies pooledCognitive Support forHuperzine
  3. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.
    Zheng W; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Sun F; D'Arcy C; Meng X; Xiang YT · Human psychopharmacology · 2017
    Meta-analysis1,117 participants12 studies pooledCognitive Support forHuperzine
  4. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.
    Xing SH; Zhu CX; Zhang R; An L · Evidence-based complementary and alternative medicine : eCAM · 2014
    Meta-analysis825 participants10 studies pooledCognitive Support Brain Health forHuperzine
  5. Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial.
    Zhang Z; Shen Y; Li J; Tang Y; Zhou P; Ying T; Mo R; Ru Z; Zhao G; Zhu J; Li S; Zhao H · International journal of surgery (London, England) · 2026
    Randomized trial123 participantsCognitive Support Brain Health forHuperzine
  6. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G · Zhonghua yi xue za zhi · 2002
    Randomized trial202 participantsCognitive Support Brain Health forHuperzine
  7. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.
    Wang BS; Wang H; Wei ZH; Song YY; Zhang L; Chen HZ · Journal of neural transmission (Vienna, Austria : 1996) · 2009
    Meta-analysis4 studies pooledCognitive Support forHuperzine
  8. Huperzine A for Alzheimer's disease.
    Li J; Wu HM; Zhou RL; Liu GJ; Dong BR · The Cochrane database of systematic reviews · 2008
    Meta-analysis454 participants6 studies pooledCognitive Support forHuperzine
  9. The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.
    Perng CH; Chang YC; Tzang RF · Psychopharmacology · 2019
    Meta-analysis44,854 participants235 studies pooledCognitive Support forHuperzine
  10. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis.
    Cui CC; Sun Y; Wang XY; Zhang Y; Xing Y · Medicine · 2019
    Meta-analysis33 studies pooledCognitive Support forHuperzine
  11. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.
    Malaguarnera M; Gargante MP; Cristaldi E; Vacante M; Risino C; Cammalleri L; Pennisi G; Rampello L · Digestive diseases and sciences · 2008
    Randomized trial125 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  12. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M · Neurology · 1991
    Randomized trial130 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  13. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome.
    Herrmann WM; Dietrich B; Hiersemenzel R · International journal of clinical pharmacology research · 1990
    Randomized trialBrain Health forAcetyl L-Carnitine
  14. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.
    Malaguarnera M; Vacante M; Motta M; Giordano M; Malaguarnera G; Bella R; Nunnari G; Rampello L; Pennisi G · Metabolic brain disease · 2012
    Randomized trial61 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  15. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U · International journal of clinical pharmacology research · 1990
    Randomized trial60 participantsBrain Health Mental Focus forAcetyl L-Carnitine
  16. Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis.
    Tiemtad P; Ingkaninan K; Temkitthawon P; Thimkorn P; Rattanachaisit N; Teaktong T; Dhippayom T · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
    Meta-analysis2,107 participants29 studies pooledBrain Health Mental Focus forBacopa
  17. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract.
    Kongkeaw C; Dilokthornsakul P; Thanarangsarit P; Limpeanchob N; Norman Scholfield C · Journal of ethnopharmacology · 2014
    Meta-analysis518 participants9 studies pooledBrain Health Mental Focus Productivity Boost forBacopa
  18. Comparative efficacy of Medhya Rasayana,Bacopa monnieri, and Centella asiatica in enhancing memory and IQ of 8-10 year-old healthy boys: A prakriti-based double-blind, randomized controlled trial.
    Verma J; Rathi R; Anamika; Rathi B; Pandey VB · Journal of Ayurveda and integrative medicine · 2025
    Randomized trial180 participantsBrain Health Cognitive Support forBacopa
  19. Plant-derived nootropics and human cognition: A systematic review.
    Lorca C; Mulet M; Arévalo-Caro C; Sanchez MÁ; Perez A; Perrino M; Bach-Faig A; Aguilar-Martínez A; Vilella E; Gallart-Palau X; Serra A · Critical reviews in food science and nutrition · 2023
    Systematic review256 studies pooledBrain Health forBacopa
  20. The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of randomized controlled trials.
    Feng X; Fan S; Wei F · Frontiers in pharmacology · 2026
    Meta-analysis1,861 participants25 studies pooledBrain Health Cognitive Support forBacopa
  21. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
    Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L · Journal of Alzheimer's disease : JAD · 2015
    Meta-analysis2,561 participants9 studies pooledBrain Health forGinkgo
  22. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
    von Gunten A; Schlaefke S; Überla K · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017
    Meta-analysis1,628 participants4 studies pooledBrain Health Cognitive Support forGinkgo
  23. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
    Riepe M; Hoerr R; Schlaefke S · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025
    Meta-analysis782 participants4 studies pooledBrain Health Productivity Boost forGinkgo
  24. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
    Cui M; You T; Zhao Y; Liu R; Guan Y; Liu J; Liu X; Wang X; Dong Q · Frontiers in pharmacology · 2023
    Randomized trial201 participantsBrain Health Productivity Boost forGinkgo
  25. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
    Herrschaft H; Nacu A; Likhachev S; Sholomov I; Hoerr R; Schlaefke S · Journal of psychiatric research · 2012
    Randomized trial410 participantsBrain Health forGinkgo
  26. Treatment with Huperzine A improves cognition in vascular dementia patients.
    Xu ZQ; Liang XM; Juan-Wu; Zhang YF; Zhu CX; Jiang XJ · Cell biochemistry and biophysics · 2012
    Randomized trial78 participantsBrain Health forHuperzine
  27. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
    Gul A; Bakht J; Mehmood F · Journal of the Chinese Medical Association : JCMA · 2019
    Randomized trial100 participantsBrain Health forHuperzine
  28. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
    Torrioli MG; Vernacotola S; Peruzzi L; Tabolacci E; Mila M; Militerni R; Musumeci S; Ramos FJ; Frontera M; Sorge G; Marzullo E; Romeo G; Vallee L; Veneselli E; Cocchi E; Garbarino E; Moscato U; Chiurazzi P; D'Iddio S; Calvani M; Neri G · American journal of medical genetics. Part A · 2008
    Randomized trial63 participantsCognitive Support forAcetyl L-Carnitine
  29. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
    Malaguarnera M; Gargante MP; Cristaldi E; Colonna V; Messano M; Koverech A; Neri S; Vacante M; Cammalleri L; Motta M · Archives of gerontology and geriatrics · 2008
    Randomized trial96 participantsCognitive Support forAcetyl L-Carnitine
  30. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials.
    Pase MP; Kean J; Sarris J; Neale C; Scholey AB; Stough C · Journal of alternative and complementary medicine (New York, N.Y.) · 2012
    Systematic review6 studies pooledCognitive Support Productivity Boost forBacopa
  31. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations.
    Kean JD; Downey LA; Stough C · Complementary therapies in medicine · 2017
    Systematic review5 studies pooledCognitive Support forBacopa
  32. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial.
    Kumar N; Abichandani LG; Thawani V; Gharpure KJ; Naidu MU; Venkat Ramana G · Evidence-based complementary and alternative medicine : eCAM · 2024
    Randomized trial60 participantsCognitive Support forBacopa
  33. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M · Clinical therapeutics · 2003
    Randomized trial261 participantsCognitive Support forCholine
  34. Association of dietary choline intake with incidence of dementia, Alzheimer disease, and mild cognitive impairment: a large population-based prospective cohort study.
    Niu YY; Yan HY; Zhong JF; Diao ZQ; Li J; Li CP; Chen LH; Huang WQ; Xu M; Xu ZT; Liang XF; Li ZH; Liu D · The American journal of clinical nutrition · 2025
    Cohort study125,594 participantsCognitive Support forCholine
  35. Choline intake during pregnancy and child cognition at age 7 years.
    Boeke CE; Gillman MW; Hughes MD; Rifas-Shiman SL; Villamor E; Oken E · American journal of epidemiology · 2013
    Cohort study895 participantsCognitive Support forCholine
  36. Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
    Sohn M; Park YH; Lim S · Diabetes, obesity & metabolism · 2025
    Randomized trial36 participantsCognitive Support forCholine
  37. Maternal choline supplementation mitigates alcohol exposure effects on neonatal brain volumes.
    Warton FL; Molteno CD; Warton CMR; Wintermark P; Lindinger NM; Dodge NC; Zöllei L; van der Kouwe AJW; Carter RC; Jacobson JL; Jacobson SW; Meintjes EM · Alcoholism, clinical and experimental research · 2022
    Randomized trial52 participantsCognitive Support forCholine
  38. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
    Tian X; Xu Q; Xia X; Zhang Y; Meng X; Wang A · Journal of neurology · 2024
    Randomized trial3,163 participantsCognitive Support forGinkgo
  39. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF · JAMA · 1997
    Randomized trial309 participantsCognitive Support Productivity Boost forGinkgo
  40. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
    Bachinskaya N; Hoerr R; Ihl R · Neuropsychiatric disease and treatment · 2011
    Randomized trial410 participantsCognitive Support forGinkgo
  41. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O; GOTADAY Study Group · International journal of geriatric psychiatry · 2013
    Randomized trial410 participantsCognitive Support forGinkgo
  42. [Drug evaluation of huperzine A in the treatment of senile memory disorders].
    Zhang RW; Tang XC; Han YY; Sang GW; Zhang YD; Ma YX; Zhang CL; Yang RM · Zhongguo yao li xue bao = Acta pharmacologica Sinica · 1992
    Randomized trial56 participantsCognitive Support forHuperzine
  43. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.
    Malaguarnera G; Pennisi M; Gagliano C; Vacante M; Malaguarnera M; Salomone S; Drago F; Bertino G; Caraci F; Nunnari G; Malaguarnera M · Hepatitis monthly · 2014
    Randomized trial62 participantsMental Focus Productivity Boost forAcetyl L-Carnitine
  44. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration].
    Lino A; Boccia MM; Rusconi AC; Bellomonte L; Cocuroccia B · La Clinica terapeutica · 1992
    Non-randomized trial17 participantsMental Focus forAcetyl L-Carnitine
  45. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial.
    Arnold LE; Amato A; Bozzolo H; Hollway J; Cook A; Ramadan Y; Crowl L; Zhang D; Thompson S; Testa G; Kliewer V; Wigal T; McBurnett K; Manos M · Journal of child and adolescent psychopharmacology · 2008
    Randomized trial112 participantsMental Focus forAcetyl L-Carnitine
  46. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE · The Cochrane database of systematic reviews · 2019
    Meta-analysis398 participants5 studies pooledMental Focus forAcetyl L-Carnitine
  47. Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: A triple-blinded, randomized, placebo-controlled trial.
    Delfan M; Kordestani-Moghaddam P; Gholami M; Kazemi K; Mohammadi R · Explore (New York, N.Y.) · 2024
    Randomized trial62 participantsMental Focus forBacopa
  48. Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: a review and comparison of effect sizes.
    Neale C; Camfield D; Reay J; Stough C; Scholey A · British journal of clinical pharmacology · 2013
    Systematic reviewMental Focus forBacopa
  49. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review.
    Al Shahab S; Al Balushi R; Qambar A; Abdulla R; Qader M; Abdulla S; Jahrami H · Nutrients · 2025
    Systematic reviewMental Focus forBacopa
  50. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
    Hort J; Duning T; Hoerr R · Neuropsychiatric disease and treatment · 2023
    Systematic review946 participants9 studies pooledMental Focus forGinkgo
  51. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2012
    Randomized trial216 participantsMental Focus forGinkgo
  52. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Pharmacopsychiatry · 1996
    Randomized trial216 participantsMental Focus forGinkgo
  53. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.
    Li S; Zhang X; Fang Q; Zhou J; Zhang M; Wang H; Chen Y; Xu B; Wu Y; Qian L; Xu Y · Stroke and vascular neurology · 2021
    Randomized trial348 participantsMental Focus forGinkgo
  54. Ginkgo biloba in the Aging Process: A Narrative Review.
    Barbalho SM; Direito R; Laurindo LF; Marton LT; Guiguer EL; Goulart RA; Tofano RJ; Carvalho ACA; Flato UAP; Capelluppi Tofano VA; Detregiachi CRP; Bueno PCS; Girio RSJ; Araújo AC · Antioxidants (Basel, Switzerland) · 2024
    Narrative review14 studies pooledMental Focus forGinkgo
  55. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial.
    Calabrese C; Gregory WL; Leo M; Kraemer D; Bone K; Oken B · Journal of alternative and complementary medicine (New York, N.Y.) · 2009
    Randomized trial54 participantsProductivity Boost forBacopa
  56. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial.
    Stough C; Downey LA; Lloyd J; Silber B; Redman S; Hutchison C; Wesnes K; Nathan PJ · Phytotherapy research : PTR · 2009
    Randomized trial107 participantsProductivity Boost forBacopa
  57. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance.
    Downey LA; Kean J; Nemeh F; Lau A; Poll A; Gregory R; Murray M; Rourke J; Patak B; Pase MP; Zangara A; Lomas J; Scholey A; Stough C · Phytotherapy research : PTR · 2014
    Randomized trial24 participantsProductivity Boost forBacopa
  58. [Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability].
    Kasper S; Schubert H · Fortschritte der Neurologie-Psychiatrie · 2009
    Meta-analysis10 studies pooledProductivity Boost forGinkgo
  59. Dietary Flavonoids and Human Cognition: A Meta-Analysis.
    Cheng N; Bell L; Lamport DJ; Williams CM · Molecular nutrition & food research · 2022
    Meta-analysis5,519 participants80 studies pooledProductivity Boost forGinkgo
  60. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba.
    Elsabagh S; Hartley DE; File SE · Journal of psychopharmacology (Oxford, England) · 2005
    Randomized trial87 participantsProductivity Boost forGinkgo
  61. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial.
    Gavrilova SI; Preuss UW; Wong JW; Hoerr R; Kaschel R; Bachinskaya N; GIMCIPlus Study Group · International journal of geriatric psychiatry · 2015
    Randomized trial160 participantsProductivity Boost forGinkgo
  62. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers.
    Kennedy DO; Jackson PA; Haskell CF; Scholey AB · Human psychopharmacology · 2008
    Randomized trial78 participantsProductivity Boost forGinkgo
  63. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial.
    Wessinger CM; Inman CL; Weinstock J; Weiss EP · International journal of exercise science · 2025
    Randomized trial15 participantsProductivity Boost forHuperzine